Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp

Diabetes Research and Clinical Practice

Volumn 63, Issue 1, 2004, Pages 37-45

  Micic, Dragan ^a   Kendereski, Aleksandra ^a   Sumarac Dumanovic, Mirjana ^a   Cvijovic, Goran ^a   Popovic, Vera ^a   Dieguez, Carlos ^b   Casanueva, Felipe ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Euglycemic clamp; GHRH + GHRP 6; Growth hormone; Hyperglycemic clamp; Type 2 diabetes

Indexed keywords

GLUCAGON; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; MONOCOMPONENT INSULIN; NOVONORDISK;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLAMP; CLINICAL ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RESPONSE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; STATISTICAL ANALYSIS;

EID: 0346992133     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2003.08.012     Document Type: Article

References (34)

1. Kjeldsen H., Hansen A.P., Lundbaeck K. Twenty-four hour serum growth hormone levels in maturity onset diabetics. Diabetes. 24:1975;977-982.
2. Barnes A.J., Kohner E.M., Johnston D.G., Alberti K.G.M.M. Severe retinopathy and mild carbohydrate intolerance: possible role of insulin deficiency and elevated circulating growth hormone. Lancet. 1:1985;1465-1468.
3. Owens D.R., Violund A., Jones D.et al. Retinopathy in newly presenting non-insulin dependent diabetic patients. Diabetes Res. 9:1988;59-65.
4. Hansen A.P. Abnormal serum growth hormone response to exercise in maturity-onset diabetics. Diabetes. 22:1973;619-628.
5. Copelman P.G., Mason A.G., Noonan K., Monson J.P. Impaired growth hormone responses to growth hormone releasing factor in diabetic men. Clin. Endocrinol. 28:1984;33-38.
6. Giustina A., Bresciani E., Tassi C., Valentini U., Wehrenberg W.B. Effect of pyridostigmine on the growth hormone response to growth hormone releasing hormone in lean and obese and type 2 diabetic patients. Metabolism. 43:1994;893-898.
7. Richards N.T., Wood S.M., Christofides N.D., Bhuttacharji S.C., Bloom S.R. Impaired growth hormone response to human pancreatic growth hormone releasing factor (GRF (1-44)) in type 2 (non-insulin dependent) diabetes. Diabetologia. 27:1984;529-534.
8. Giustina A., Veldhuis J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Rev. 19:1998;717-797.
9. Micic D., Macut Dj., Popovic V.et al. Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus. Metabolism. 48:1999;525-530.
10. Pietschmann P., Schernthaner G. Effect of growth hormone releasing hormone on growth hormone secretion in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 30:1987;13-15.
11. Koev D., Zacharieva S., Popova J., Andonova K. Effect of growth hormone releasing hormone on growth hormone, prostaglandin E2 and insulin in non-insulin-dependent diabetic patients. Methods Find Exp. Clin. Pharmacol. 2:1996;137-140.
12. Popovic V., Leal A., Micic D.et al. GH-releasing hormone and GH-releasing peptide 6 for diagnostic testing in GH-deficient adults. Lancet. 356:2000;1137-1142.
13. De Fronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237:1979;E214-E223.
14. Lundbaek K., Christensen N.J., Jensen V.A.et al. Diabetes, diabetic angiopathy, and growth hormone. Lancet. 11:1970;131-133.
15. Orskov H. Somatostatin, growth hormone, insulin-like growth factor-1, diabetes: friends or foes? Metabolism. 45(Suppl. 8):1996;91-95.
16. Sonksen P.H., Russell-Jones D., Jones R.H. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and glimpse into the future. Horm. Res. 40:1993;68-79.
17. Wilson S.H., Davis M.I., Caballero S., Grant M.B. Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Horm. IGF Res. 11(Suppl. A):2001;S53-S59.
18. Janssen J.A., Lamberts S.W. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin. Endocrinol. 52:2000;1-9.
19. Clemmons D.R., Moses A.C., McKay M.J., Sommer A., Rosen D.M., Ruckie J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J. Clin. Endocrinol. Metab. 85:2000;1518-1524.
20. Flyvbjerg A. Potential use of growth hormone receptor antagonist in the treatment of diabetic kidney disease. Growth Horm. IGF Res. 11(Suppl. A):2001;S115-S119.
21. Clasey J.L., Weltman A., Patrie J.et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release Independent of age, gender, and other physiological factors. J. Clin. Endocrinol. Metab. 86:2001;3845-3852.
22. Masuda A., Shibasaki T., Nakahara M.et al. The effect of glucose on growth hormone (GH)-releasing hormone-mediated GH secretion in man. J. Clin. Endocrinol. Metab. 60:1985;523-526.
23. Giustina A., Bossoni S., Cimino A., Pizzocolo G., Romanelli G., Wehrenberg W.B. Impaired growth hormone response to pyridostigmine in type I diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. J. Clin. Endocrinol. Metab. 71:1990;1486-1490.
24. Wass J.A.H., Penman E., Dryburgh J.R.et al. Circulating somatostatin after food and glucose in man. J. Clin. Endocrinol. 12:1980;569-574.
25. Hunter W.M., Willoughby J.M.T., Strong J.A. Plasma insulin and growth hormone during 22-hours fasts and after graded glucose loads in six healthy adults. J. Endocrinol. 40:1968;297-311.
26. Kopelman P.G., Mason A.C., Noonan K., Monson J.P. Growth hormone response to growth hormone releasing factor in diabetic men. Clin. Endocrinol. 28:1988;33-38.
27. Ceda G.P., Hoffman A.R., Silverberg G.D., Wilson D.M., Rosenfeld R.G. Regulation of growth hormone release from cultured human pituitary adenomas by somatomedins and insulin. J. Clin. Endocrinol. Metab. 60:1985;1204-1209.
28. Sharp P.S., Mohan V., Maneschi F.et al. Changes in plasma growth hormone in diabetic and nondiabetic subjects during the glucose clamp. Metabolism. 1:1987;71-75.
29. Press M., Caprio S., Tamborlane W.V.et al. Pituitary response to growth hormone-releasing hormone in IDDM: abnormal responses to insulin and hyperglycemia. Diabetes. 41:1992;17-21.
30. Martina V., Bruno G., Tagliabue M.et al. Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus. Horm. Metab. Res. 27:1995;26-30.
31. Delitala G., Tomasi P.A., Palermo M., Fresu P. Interaction of glucose and pyridostigmine on the secretion of growth hormone (GH) induced by GH-releasing hormone (GHRH). J. Endocrinol. Invest. 13:1990;653-656.
32. Popovic V., Damjanovic S., Micic D., Djurovic M., Dieguez C., Casanueva F.F. Blocked growth hormone-releasing peptide (GHRP-6)-induced secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J. Clin. Endocrinol. Metab. 80:1995;942-947.
33. Shaffer Tannenbaum G., Bowers C.Y. Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin. Endocrine. 14:2001;21-27.
34. Camanni F., Ghigo E., Arvat E. Growth hormone releasing peptides and their analogs. Front Neuroendocrinol. 19:1998;47-72.